DGIdb - RASAGILINE Drug Record

RASAGILINE chembl:CHEMBL887 Approved

Alternate Names:

TV-1030
AGN-1135
RASAGILINE
AZILECT
(1R)-N-PROPARGYLINDAN-1-AMINE
(R)-INDAN-1-YL-PROP-2-YNYL-AMINE
(R)-N-2-PROPYNYL-1-INDANAMINE
RAS
TVP-1012
AZILECT®
chembl:CHEMBL887
chemidplus:136236-51-6
rxcui:134748
pubchem.compound:3052776
drugbank:01367

Drug Info:

FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antiparkinson agent
Drug Class	antiparkinson agents
Year of Approval	2006
Drug Categories	serotonin modulators
Drug Categories	agents that produce hypertension
Drug Categories	agents that reduce seizure threshold
Drug Categories	antidepressive agents
Drug Categories	central nervous system depressants
Drug Categories	compounds used in a research, industrial, or household setting
Drug Categories	cytochrome p-450 substrates
Drug Categories	drugs that are mainly renally excreted
Drug Categories	serotonergic drugs shown to increase risk of serotonin syndrome
Drug Categories	serotonin agents

(3 More Sources)

Publications:

Youdim et al., 2001, Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]., Cell. Mol. Neurobiol.
Naoi et al., 2009, Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease., Expert Rev Neurother
Uzun et al., Investigation of oral selegiline and rasagiline administration on QT interval in conscious rabbits., Eur Rev Med Pharmacol Sci
Chau et al., 2010, Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells., Neurochem. Int.
Chen et al., 2007, Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease., Clin Ther
Youdim et al., Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition., J. Neurosci. Res.
Weinreb et al., 2010, Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity., Prog. Neurobiol.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Leegwater-Kim et al., 2010, The role of rasagiline in the treatment of Parkinson's disease., Clin Interv Aging
Masellis M et al., 2016, Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study., Brain
Youdim et al., 2003, The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline., Biochem. Pharmacol.
Bar-Am et al., 2005, Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine., FASEB J.
Maruyama et al., Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes., Neurotoxicol Teratol
Akao et al., 2002, An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells., Neurosci. Lett.

RASAGILINE MAOB

Interaction Score: 3.9

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name rasagiline mesylate, TVP-1012,Agilect

Novel drug target Established target

Specific Action of the Ligand Inhibition

PMIDs:
12043833 19673610 19499843 20624440 18035186 15573406 20600573 11752352 20517484

Sources:
TEND TdgClinicalTrial TTD DrugBank GuideToPharmacology
RASAGILINE BCL2

Interaction Score: 2.32

Interaction Types & Directionality:

activator (activating)

Interaction Info:

PMIDs:
14555244 16148027 12043833 12200198 12057839

Sources:
DrugBank
RASAGILINE DRD2

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27190009

Sources:
PharmGKB

DrugBank: DB01367

Version: 5.1.7

Alternate Names:

RASAGILINE DrugBank Drug Name

136236-51-6 CAS Number

Apo-rasagiline Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories agents that produce hypertension

Publications:

Youdim et al., 2003, The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline., Biochem. Pharmacol.

Bar-Am et al., 2005, Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine., FASEB J.

Youdim et al., 2001, Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]., Cell. Mol. Neurobiol.

TEND: RASAGILINE
- Version: 01-August-2011
Alternate Names:

RASAGILINE Primary Drug Name

Drug Info:

Year of Approval 2006

Drug Class antiparkinson agents

Publications:
TdgClinicalTrial: RASAGILINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antiparkinson agent

Drug Class Small Molecule

FDA Approval approved

Publications:
PharmGKB: rasagiline
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Masellis M et al., 2016, Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study., Brain
GuideToPharmacology: 178103254
- Version: 29-September-2020
Alternate Names:

RASAGILINE GuideToPharmacology Ligand Name

Drug Info:

Publications:
TTD: Rasagiline
- Version: 2020.06.01
Alternate Names:

D06OMW TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL887
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	rasagiline mesylate, TVP-1012,Agilect
Novel drug target	Established target
Specific Action of the Ligand	Inhibition

RASAGILINE	DrugBank Drug Name
136236-51-6	CAS Number
Apo-rasagiline	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Categories	agents that produce hypertension

RASAGILINE Drug Record

RASAGILINE chembl:CHEMBL887 Approved

Alternate Names:

Drug Info:

Publications:

RASAGILINE MAOB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name rasagiline mesylate, TVP-1012,Agilect Novel drug target Established target Specific Action of the Ligand Inhibition

PMIDs: 12043833 19673610 19499843 20624440 18035186 15573406 20600573 11752352 20517484

Sources: TEND TdgClinicalTrial TTD DrugBank GuideToPharmacology

RASAGILINE BCL2

Interaction Types & Directionality: activator (activating)

Interaction Info:

PMIDs: 14555244 16148027 12043833 12200198 12057839

Sources: DrugBank

RASAGILINE DRD2

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27190009

Sources: PharmGKB

DrugBank: DB01367

Alternate Names: RASAGILINE DrugBank Drug Name 136236-51-6 CAS Number Apo-rasagiline Drug Brand

Drug Info: Drug Type small molecule Drug Groups approved Drug Categories agents that produce hypertension

TEND: RASAGILINE

Alternate Names: RASAGILINE Primary Drug Name

Drug Info: Year of Approval 2006 Drug Class antiparkinson agents

Publications:

TdgClinicalTrial: RASAGILINE

Alternate Names:

Drug Info: Drug Indications antiparkinson agent Drug Class Small Molecule FDA Approval approved

Publications:

PharmGKB: rasagiline

Alternate Names:

Drug Info:

Publications: Masellis M et al., 2016, Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study., Brain

GuideToPharmacology: 178103254

Alternate Names: RASAGILINE GuideToPharmacology Ligand Name

Drug Info:

Publications:

TTD: Rasagiline

Alternate Names: D06OMW TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL887

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name rasagiline mesylate, TVP-1012,Agilect

Novel drug target Established target

Specific Action of the Ligand Inhibition

PMIDs:
12043833 19673610 19499843 20624440 18035186 15573406 20600573 11752352 20517484

Sources:
TEND TdgClinicalTrial TTD DrugBank GuideToPharmacology

Interaction Types & Directionality:

activator (activating)

PMIDs:
14555244 16148027 12043833 12200198 12057839

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
27190009

Sources:
PharmGKB

Alternate Names:

RASAGILINE DrugBank Drug Name

136236-51-6 CAS Number

Apo-rasagiline Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Categories agents that produce hypertension

Alternate Names:

RASAGILINE Primary Drug Name

Drug Info:

Year of Approval 2006

Drug Class antiparkinson agents

Drug Info:

Drug Indications antiparkinson agent

Drug Class Small Molecule

FDA Approval approved

Publications:

Masellis M et al., 2016, Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study., Brain

Alternate Names:

RASAGILINE GuideToPharmacology Ligand Name

Alternate Names:

D06OMW TTD Drug ID